Compare Piramal Healthcare with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs PANACEA BIOTECH - Comparison Results

PIRAMAL ENTERPRISES     Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES PANACEA BIOTECH PIRAMAL ENTERPRISES/
PANACEA BIOTECH
 
P/E (TTM) x 16.7 8.8 190.1% View Chart
P/BV x 1.1 3.4 33.5% View Chart
Dividend Yield % 2.0 0.0 -  

Financials

 PIRAMAL ENTERPRISES   PANACEA BIOTECH
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-19
PANACEA BIOTECH
Mar-19
PIRAMAL ENTERPRISES/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs3,303354 934.0%   
Low Rs1,797138 1,300.1%   
Sales per share (Unadj.) Rs716.574.6 960.9%  
Earnings per share (Unadj.) Rs79.76.7 1,193.3%  
Cash flow per share (Unadj.) Rs107.915.5 696.3%  
Dividends per share (Unadj.) Rs28.000-  
Dividend yield (eoy) %1.10-  
Book value per share (Unadj.) Rs1,477.557.2 2,582.7%  
Shares outstanding (eoy) m184.4561.25 301.1%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x3.63.3 107.9%   
Avg P/E ratio x32.036.8 86.9%  
P/CF ratio (eoy) x23.615.9 148.9%  
Price / Book Value ratio x1.74.3 40.1%  
Dividend payout %35.10-   
Avg Mkt Cap Rs m470,29215,061 3,122.5%   
No. of employees `0007.82.3 337.9%   
Total wages/salary Rs m22,5041,471 1,530.0%   
Avg. sales/employee Rs Th16,899.41,973.6 856.3%   
Avg. wages/employee Rs Th2,877.7635.6 452.7%   
Avg. net profit/employee Rs Th1,879.9176.8 1,063.4%   
INCOME DATA
Net Sales Rs m132,1534,567 2,893.7%  
Other income Rs m3,12845 6,982.1%   
Total revenues Rs m135,2814,612 2,933.4%   
Gross profit Rs m66,2902,030 3,266.0%  
Depreciation Rs m5,202540 963.2%   
Interest Rs m44,0971,048 4,206.6%   
Profit before tax Rs m20,119486 4,137.9%   
Minority Interest Rs m3,1940-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,61177 11,169.0%   
Profit after tax Rs m14,701409 3,593.5%  
Gross profit margin %50.244.4 112.9%  
Effective tax rate %42.815.9 269.9%   
Net profit margin %11.19.0 124.2%  
BALANCE SHEET DATA
Current assets Rs m122,7422,415 5,083.5%   
Current liabilities Rs m310,8109,077 3,424.0%   
Net working cap to sales %-142.3-145.9 97.5%  
Current ratio x0.40.3 148.5%  
Inventory Days Days2365 35.4%  
Debtors Days Days3971 54.8%  
Net fixed assets Rs m116,9048,333 1,402.9%   
Share capital Rs m36961 601.8%   
"Free" reserves Rs m272,1613,443 7,905.4%   
Net worth Rs m272,5303,504 7,777.7%   
Long term debt Rs m270,196461 58,585.5%   
Total assets Rs m856,26113,755 6,225.0%  
Interest coverage x1.51.5 99.5%   
Debt to equity ratio x1.00.1 753.3%  
Sales to assets ratio x0.20.3 46.5%   
Return on assets %6.910.6 64.8%  
Return on equity %5.411.7 46.2%  
Return on capital %12.438.7 32.1%  
Exports to sales %020.9 0.0%   
Imports to sales %08.1 0.0%   
Exports (fob) Rs mNA954 0.0%   
Imports (cif) Rs mNA372 0.0%   
Fx inflow Rs m15,2001,203 1,263.5%   
Fx outflow Rs m4,889467 1,047.6%   
Net fx Rs m10,312736 1,400.3%   
CASH FLOW
From Operations Rs m-115,9751,049 -11,057.8%  
From Investments Rs m-8,265-54 15,448.8%  
From Financial Activity Rs m107,525-1,011 -10,631.3%  
Net Cashflow Rs m-16,650-20 84,518.8%  

Share Holding

Indian Promoters % 52.9 74.5 71.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 0.6 666.7%  
FIIs % 26.6 1.3 2,046.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 23.6 69.9%  
Shareholders   93,274 10,259 909.2%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  UNICHEM LAB  ALKEM LABORATORIES  CADILA HEALTHCARE  

Compare PIRAMAL ENTERPRISES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 429 Points Higher; Auto and IT Stocks Rally(Closing)

Indian share markets extended gains for the second consecutive day and ended on a strong note, tracking gains in Asian peers and Wall Street.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY20); Net Profit Up 11.7% (Quarterly Result Update)

Feb 5, 2020 | Updated on Feb 5, 2020

For the quarter ended December 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 11.7% YoY). Sales on the other hand came in at Rs 38 bn (up 9.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY20); Net Profit Up 16.5% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 16.5% YoY). Sales on the other hand came in at Rs 36 bn (up 14.6% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY19); Net Profit Down 91.4% (Quarterly Result Update)

Apr 30, 2019 | Updated on Apr 30, 2019

For the quarter ended March 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 3 bn (down 91.4% YoY). Sales on the other hand came in at Rs 37 bn (up 23.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

More Views on News

Most Popular

This is How You Should Trade Intraday(Fast Profits Daily)

Jun 19, 2020

In this video, I'll show you how to trade the market intraday like a professional trader.

Be Prepared to Profit from the Coming Crash in Oil Prices(Fast Profits Daily)

Jun 25, 2020

The stability in crude oil prices will not last much longer. Be ready to make fast profits when the time comes to short crude.

Tata Motors Tripled in 18 Months but You Can Do Even Better. Here's How...(Profit Hunter)

Jun 24, 2020

Rahul is ready for a repeat of his famous 2008 Tata Motors call.

This Ratio Says Smallcaps Are Your Best Bet to Ride the Post Covid Market Rebound(Profit Hunter)

Jun 23, 2020

Here's why I believe that post Covid rebound in smallcaps will be much sharper than largecaps.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Jul 2, 2020 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES - STERLING BIOTECH COMPARISON

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS